TABLE 1

Subject characteristics and treatment period length

Subject CharacteristicsStudy 1: StaggeredStudy 2: Simultaneous
Race
    Caucasian (Non-Hispanic/Latino)149
    Asian10
    Black/African American10
Gender
    Male53
    Female116
Age (years)
    Mean ± S.D.33 ± 929 ± 9
    Range20–5018–42
Weight (kg)
    Mean ± S.D.78 ± 1479 ± 14
    Range60–10059–105
Treatment period days: average (minimum, maximum)
    Ritonavir (200 mg t.i.d. day 1, 300 mg b.i.d. days 2–7, 400 mg b.i.d. > day 8, dose escalation to minimize GI irritation)14 (14, 15)15 (15, 15)
    Nelfinavir (1250 mg b.i.d.)14 (13, 16)14 (14, 15)
    Rifampin (600 mg q.d.)14 (12, 15)15 (14, 15)
Probe drug administration
    Cocktail A2 mg p.o. of midazolam at approximately 8:00 AM and 0.5 mg p.o. of digoxin at approximately 9:00 AM (24-h blood and urine collection)
    Cocktail B1 mg i.v. of midazolam, 30 mg p.o. of dextromethorphan, 500 mg p.o. of tolbutamide, and 200 mg p.o. of caffeine at approximately 8:00 AM (24-h blood and urine collection)
    Bupropion150 mg p.o. extended-release bupropion at approximately 8:00 AM (48-h blood and urine collection)